The ATP Binding Cassette Sub Family G Member 2 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family G Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ATP Binding Cassette Sub Family G Member 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Ovarian Cancer. It also reviews key players involved in ATP Binding Cassette Sub Family G Member 2 targeted therapeutics development with respective active and dormant or discontinued products.
The ATP Binding Cassette Sub Family G Member 2 pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 3, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
ATP Binding Cassette Sub Family G Member 2 overview
ATP binding cassette subfamily G member 2 is a protein encoded by ABCG2 gene. ABCG2 is also known as CDw338 (cluster of differentiation w338). This protein is included in the superfamily of ATP-binding cassette (ABC) transporters. Alternatively referred to as a breast cancer resistance protein, this protein functions as a xenobiotic transporter which may play a major role in multi-drug resistance. It likely serves as a cellular defense mechanism in response to mitoxantrone and anthracycline exposure. Significant expression of this protein has been observed in the placenta, which may suggest a potential role for this molecule in placenta tissue.
For a complete picture of ATP Binding Cassette Sub Family G Member 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
